Korean J Intern Med.  2016 May;31(3):433-443. 10.3904/kjim.2015.074.

Chronic lymphocytic leukemia: a clinical review including Korean cohorts

• Jeon YW
• Cho SG

• KMID: 2163499
• DOI: http://doi.org/10.3904/kjim.2015.074

Abstract

Only 5th decade ago, chronic lymphocytic leukemia (CLL) was only recognized as disease group of presenting features like peripheral lymphocytosis, organomegaly including of splenomegaly. As understanding of disease biology and molecular diagnostic tools are getting improved gradually, characterization of variation in CLL's clinical courses was facilitated, resulting in better risk stratification and targeted treatments. Consequently multiple new targeted agents have been used in treatment of CLL, it makes improved clinical outcome. Rituximab containing chemoimmunotherapy (combination of rituximab, fludarabine, and cyclophosphamide) have shown better overall response rate and progression-free survival on fit patients' group in front-line setting, result in standard first-line therapeutic option for CLL. Furthermore, after introducing that the B-cell receptor is crucial for the evolution and progression of CLL, emerging treatments targeting highly activated surface antigens and oncogenic signaling pathways have been associated with several successes in recent decades. These include new anti-CD 20 monoclonal antibody (obinutuzumab), the bruton tyrosine kinase inhibitor (ibrutinib), the phosphatidylinositol 3-kinase inhibitor (idelalisib), and B-cell CLL/lymphoma 2 inhibitor (ABT-199 and ABT-263). So, we discuss not only general pathophysiology of CLL, but also rapidly advancing treatment strategies that are being studied or approved for treatment of CLL.

Keyword

Leukemia, lymphocytic, chronic, B-cell; Incidence; Investigational new drug application; Korean cohort

MeSH Terms

Antigens, Surface
B-Lymphocytes
Biology
Cohort Studies*
Disease-Free Survival
Incidence
Investigational New Drug Application
Leukemia, Lymphocytic, Chronic, B-Cell*
Lymphocytosis
Pathology, Molecular
Phosphatidylinositol 3-Kinase
Protein-Tyrosine Kinases
Splenomegaly
Antigens, Surface
Phosphatidylinositol 3-Kinase
Protein-Tyrosine Kinases